Grifols SA (NASDAQ:GRFS)

32.86
Delayed Data
As of May 22
 +0.13 / +0.40%
Today’s Change
29.24
Today|||52-Week Range
46.66
-3.32%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$4.3B

Company Description

Grifols SA is a vertically integrated global producer of plasma derivatives. Its activities include sourcing raw material, manufacturing various plasma derivative products and selling and distributing final products to healthcare providers. The company operates through four segments: Bioessence, Hospital, Diagnostic & Raw Materials. The Bioessence segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by Group companies earmarked for hospital pharmacy. The Diagnostic segment includes the marketing of diagnostic testing equipment, reagents, and other equipment. The Raw Materials segment includes the sale of intermediate biological products and the rendering of manufacturing services to third party companies. The company applies sophisticated science and technology to improve people's health and well-being through providing life-saving products. Grifols was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

Contact Information

Grifols SA
Avinguda de la Generalitat, 152-158
Barcelona Catalonia 08174
P:(493) 571-0500
Investor Relations:

Employees

Shareholders

Other institutional34.48%
Mutual fund holders26.42%
Individual stakeholders--

Top Executives

Víctor Grifols RouraChairman, President & Chief Executive Officer
Alfredo Arroyo GuerraChief Financial Officer & Vice President
Eva Bastida TubauVP, Director-Scientific & Medical Affairs
Carlos Roura FernandezVP & Co-President-Global Industrial Division
Montserrat Lloveras CalvoVP, Director-Corporate Accounting & Reporting

To view my watchlist

Not a member yet?

Sign up now for a free account